

## FACTOR XIII (HUMAN)

<b>OTHER NAMES</b>	Factor XIII Concentrate, Corifact™
<b>PRODUCT COMPOSITION</b>	Product is a purified, sterile, lyophilized concentrate of human blood coagulation factor XIII. Factor XIII concentrate is cell-free and therefore is administered without regard to patient ABO or Rh type. Product is packed in quantities of either 250IU or 1250IU.
<b>INFORMED CONSENT</b>	Required
<b>ALTERNATIVES</b>	<b>Non-blood Product:</b> None
	<b>Blood Product:</b> None
<b>DOSAGE</b>	<ul style="list-style-type: none"> <li>• Dosage and duration of treatment will depend on the patient factor deficiency and the circumstances necessitating the treatment</li> <li>• The manufacturer product monograph will provide specific dosage guidelines</li> <li>• Ordered as IU (international units) and a timed frequency (e.g. Q2h)</li> <li>• Transfusion Medicine (TM) will provide the dose requested <math>\pm 10\%</math> depending on available vial sizes</li> </ul>
<b>ADMINISTRATION</b>	<ul style="list-style-type: none"> <li>• Reconstituted and filtered by TM and supplied to unit in a syringe</li> <li>• Product is best given immediately after preparation, <b>MUST</b> be within 3 hours of reconstitution</li> <li>• Should be inspected visually for particulate matter and discoloration prior to administration</li> <li>• Should be given IV direct push, no more than 4ml per minute</li> <li>• Flush tubing pre and post infusion with 0.9% NaCl</li> </ul> <p><b>Administer the entire amount</b></p>
<b>DIAGNOSTIC MONITORING</b>	<p><b>Vital sign monitoring as per hospital policy for any blood, blood component and other related product.</b> In the event of an immediate or suspected transfusion reaction, refer to hospital policy and procedures.</p> <ul style="list-style-type: none"> <li>• Allergic / Anaphylactic reactions have been noted; it is suggested to remain with patient at least 5 minutes following administration</li> </ul>
<b>CLINICAL INDICATIONS</b>	Factor XI is indicated for the control and prevention of bleeding episodes in patients with either congenital Factor XIII deficiency.
<b>SPECIAL CONSIDERATIONS</b>	<ul style="list-style-type: none"> <li>• TM will need approximately 30 minutes preparation time</li> <li>• TM needs prompt notification of changes of both dosage and/or frequency</li> <li>• Factor XIII concentrates have been associated with the development of thromboembolic complications and should be used with caution in patients with signs of fibrinolysis and DIC</li> <li>• FACTOR XIII is not approved for general use in Canada and requires special approval from the Public Health Agency of Canada (PHAC), contact TM (local 68003)</li> </ul>
<b>STORAGE CONDITIONS</b>	DO NOT REFRIGERATE AFTER RECONSTITUTION
<b>REFERENCES</b>	<b>Review product monograph</b>